Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
Independent analyses of the Phase III DCVax-L trial for glioblastoma reveal that the treatment's survival extension was likely underestimated in the original cohort-based review. Using individual patient data, statisticians found a median survival advantage of 4.9 to 6.3 months, significantly higher than the 2.8 months previously reported. The updated Hazard Ratios ranged from 0.69 to 0.77 with p-values between 0.004 and 0.027, indicating a statistically significant reduction in the risk of death. Sensitivity analyses confirmed that these results were not driven by hidden imbalances between the DCVax-L patients and control groups.
Key figures
- Drug Name
- DCVax-L
- Phase Of Trial
- Phase III
- P value range
- 0.004-0.027
- Patient count
- 331
- Hazard ratio range
- 0.69-0.77
- Survival advantage months psm low
- 4.9
- Survival advantage months original
- 2.8
- Survival advantage months psm high
- 6.3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.